5-叔丁基-2-甲基呋喃-3-羧酸 | 38422-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-叔丁基-2-甲基呋喃-3-羧酸
• 中文别名: 5-叔-丁基-2-甲基呋喃-3-羧酸
• 英文名称: 5-(tert-butyl)-2-methylfuran-3-carboxylic acid
• 英文别名: 5-tert-butyl-2-methyl-furan-3-carboxylic acid；5-tert-Butyl-2-methyl-furan-3-carbonsaeure；5-tert-butyl-2-methyl-3-furancarboxylic acid；5-tert-butyl-2-methylfuran-3-carboxylic acid；2-Methyl-5-t-butyl-furan-3-carbonsaeure
• CAS: 38422-62-7
• 化学式: C₁₀H₁₄O₃
• mdl: MFCD00221068
• 分子量: 182.219
• InChiKey: NWWAPYOVUAEIJB-UHFFFAOYSA-N

物化性质

• 熔点：
  89-92°C
• 沸点：
  280.8±28.0 °C(Predicted)
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2932190090
• 安全说明：
  S26,S36/37/39

反应信息

• 作为反应物：
  描述：

  5-叔丁基-2-甲基呋喃-3-羧酸 、 3-氨基-3-(3-氟苯基)丙酸甲酯 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1)

  摘要：

  All-trans-retinoic acid (ATRA), the biologically active metabolite of vitamin A, is used medicinally for the treatment of hyperproliferative diseases and cancers. However, it is easily metabolized. In this study, the leading compound S8 was found based on virtual screening. To improve the activity of the leading compound S8, a series of novel S8 derivatives were designed, synthesized and evaluated for their in vitro biological activities.All of the prepared compounds showed that substituting the 5-chloro-3-methyl-1-phenyl-1H-pyrazole group for the 2-tertbutyl-5-methylfuran scaffold led to a clear increase in the biological activity. The most promising compound 32, with a CYP26A1 IC50 value of 1.36 mu M (compared to liarozole (IC50 = 2.45 mu M) and S8 (IC50 = 3.21 mu M)) displayed strong inhibitory and differentiation activity against HL60 cells. In addition, the study focused on the effect of beta-phenylalanine, which forms the coordination bond with the heme of CYP26A1. These studies suggest that the compound 32 can be used as an appropriate candidate for future development. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.036
• 作为产物：
  描述：

  2-methyl-5-(tert-butyl)furan-3-carboxylic acid ethyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以83.9%的产率得到5-叔丁基-2-甲基呋喃-3-羧酸
  参考文献：
  名称：

  Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1)

  摘要：

  All-trans-retinoic acid (ATRA), the biologically active metabolite of vitamin A, is used medicinally for the treatment of hyperproliferative diseases and cancers. However, it is easily metabolized. In this study, the leading compound S8 was found based on virtual screening. To improve the activity of the leading compound S8, a series of novel S8 derivatives were designed, synthesized and evaluated for their in vitro biological activities.All of the prepared compounds showed that substituting the 5-chloro-3-methyl-1-phenyl-1H-pyrazole group for the 2-tertbutyl-5-methylfuran scaffold led to a clear increase in the biological activity. The most promising compound 32, with a CYP26A1 IC50 value of 1.36 mu M (compared to liarozole (IC50 = 2.45 mu M) and S8 (IC50 = 3.21 mu M)) displayed strong inhibitory and differentiation activity against HL60 cells. In addition, the study focused on the effect of beta-phenylalanine, which forms the coordination bond with the heme of CYP26A1. These studies suggest that the compound 32 can be used as an appropriate candidate for future development. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.036

文献信息

• 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors
  申请人：Broughton Barff Howard

  公开号：US20070225267A1

  公开（公告）日：2007-09-27

  The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.

  本发明提供了化学式（I）的BACE抑制剂；以及它们的使用和制备方法，以及用于它们制备的中间体。
• [DE] SUBSTITUIERTE 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-d]PYRIMIDIN-2-YL- UND 5, 6, 7, 8-TETRAHYDRO-CHINAZOLIN-2-YL-VERBINDUNGEN<br/>[EN] SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS<br/>[FR] COMPOSES DE 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL ET DE 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL SUBSTITUEES
  申请人：GRUENENTHAL GMBH

  公开号：WO2005105759A1

  公开（公告）日：2005-11-10

  Die vorliegende Erfindung betrifft substituierte 5,6,7,8-Tetrahydro-pyrido[4,3-­d]pyrimidin-2-yl- und 5,6,7,8-Tetrahydro-chinazolin-2-yl-Verbindungen, Verfahren zu ihrer Herstellung, Arzneimittel enthaltend diese Verbindungen sowie deren Verwendung zur Herstellung von Arzneimitteln.

  这项发明涉及取代的5,6,7,8-四氢-吡啶并[4,3-d]嘧啶-2-基和5,6,7,8-四氢-喹唑啉-2-基化合物，其制备方法，含有这些化合物的药物以及它们用于制备药物的用途。
• Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds
  申请人：Oberboersch Stefan

  公开号：US20070249631A1

  公开（公告）日：2007-10-25

  Substituted 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl and 5,6,7,8-tetrahydro-quinazolin-2-yl compounds, corresponding to formula I processes for the production thereof, pharmaceutical preparations containing these compounds the use thereof for the production of pharmaceutical preparations and related method of treating or inhibiting certain disorders or conditions, including pain.

  将5,6,7,8-四氢吡啶并[4,3-d]嘧啶-2-基和5,6,7,8-四氢喹唑啉-2-基化合物替代为公式I，生产这些化合物的方法，含有这些化合物的药物制剂，以及利用它们生产药物制剂和相关方法治疗或抑制某些疾病或症状，包括疼痛。
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE PROTEINES KINASES
  申请人：IRM LLC

  公开号：WO2005123719A1

  公开（公告）日：2005-12-29

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2 2, MKK4, c-RAF, MKK6, SAPK2 and SAPK2 kinases.

  该发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或障碍的方法，特别是涉及Abl、BCR-Abl、PDGF-R、trkB、c-SRC、BMX、FGFR3、b-RAF、SGK、Tie2、Lck、JNK2 2、MKK4、c-RAF、MKK6、SAPK2和SAPK2激酶异常激活的疾病或障碍。
• [EN] NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1).<br/>[FR] NOUVEAUX AMIDES HETEROCYCLIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004096784A1

  公开（公告）日：2004-11-11

  The present invention relates to new compounds of formula I, wherein R1 to R8 are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  本发明涉及公式I的新化合物，其中R1至R8如公式I中所定义，或其盐、溶剂合物或溶剂化合盐，以及用于其制备的新中间体，含有所述化合物的药物组合物以及所述化合物在治疗中的用途。